Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 15/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4193633 | 0.89 | FASN (0.61) | FASNCCR1 | |
| SCHEMBL4191253 | 0.89 | FASN (0.63) | FASNMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL4197020 | 0.89 | FASN (0.59) | FASNTSHR | |
| SCHEMBL4205027 | 0.87 | FASN (0.57) | FASNALDH1A1TSHRLMNAMGLL | |
| SCHEMBL4208200 | 0.86 | FASN (0.70) | FASN | |
| SCHEMBL4202962 | 0.83 | FASN (0.61) | FASNCCR1 | |
| SCHEMBL4198976 | 0.83 | FASN (0.60) | FASN | |
| SCHEMBL4203819 | 0.82 | FASN (0.59) | FASN | |
| SCHEMBL4205261 | 0.82 | FASN (0.59) | FASNLMNA | |
| SCHEMBL4177027 | 0.82 | FASN (0.54) | FASNMEN1KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118332-A1 | Therapeutic Agents - 551 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | claimed |
| US-20090118332-A1 | Therapeutic Agents - 551 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118332-A1 | Therapeutic Agents - 551 | GPR119, FABP4, FASN | FASN 3/4885MEN1 4031/4885KMT2A 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.